06660 AIM VACCINE
- 4.210
- -0.100-2.32%
AIM VACCINE News
AeMI vaccine [06660] is now trading at 4.46 Hong Kong dollars, with a 12.34% increase.
As of 13:25, Ami Vaccine [06660] reported HKD 4.46, up HKD 0.49 or 12.34% from yesterday's closing price of HKD 3.97. The trading volume was HKD 1.9948 million. The highest price today was HKD 4.46, and the lowest price was HKD 3.95. Based on the closing price yesterday, the 10-day average price was HKD 7.82, and the 50-day average price was HKD 8.30. The current P/E ratio is -6.27 times, and the 14-day strength index is 21.13.
Aimai Vaccine (06660) fell by 43.80%, now trading at 4.180 yuan, hitting a 52-week low.
As of 11:47, the price of Amy vaccine (06660) fell by 43.80% from the previous close, now at 4.180 yuan, hitting a 52-week low; the volume is 0.2268 million shares, with a turnover of 0.9536 million Hong Kong dollars.
AIM Vaccine Co., Ltd. (HKG:6660) Not Doing Enough For Some Investors As Its Shares Slump 30%
AIM Vaccine Co. Narrows Losses in H1 2024
AIM Vaccine Elevates Two Directors to Executives
AIM Vaccine Announces Board and Committee Structure
AIM Vaccine Advances MRNA Vaccine Trials
AstraZeneca vaccine (06660): Zhou Jie and Zhou Xin have been appointed as executive directors and appointed as executive directors.
Aimee Vaccine (06660) announced that Mr. Zhou Jie and Mr. Zhou Xin have been transferred from non-executive directors to executive directors, and ...
AIM VACCINE: 2024 INTERIM REPORT
Express News | AIM Vaccine H1 Gross Margin 72.3%
Express News | AIM Vaccine H1 Gross Profit RMB 388.3 Million
Express News | AIM Vaccine H1 Revenue RMB 537.2 Million
Express News | AIM Vaccine H1 Capex RMB 119.5 Million
AIM VACCINE: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Express News | AIM Vaccine - Jie Zhou and Xin Zhou Re-Designated From Non-Executive Directors to Executive Directors
AIM Immune (06660): mRNA RSV and mRNA herpes zoster vaccine submitted clinical trial pre-application to the FDA.
Aimee Vaccine (06660) announced that the group actively promotes the development of the vaccine product pipeline according to the established company's global strategy...
Aimee vaccine (06660.HK): Formal submission of clinical trial application for tetanus toxoid vaccine.
On August 29th, Aimee Vaccines (06660.HK) announced that the Group's adsorbed tetanus vaccine has formally submitted a clinical trial application to the China Drug Administration Drug Evaluation Center (CDE) in August 2024. The development of this vaccine is in line with the company's product development strategy and is an important step towards the development of multi-valent products. It will further enhance the company's product line and consolidate its industry position in the field of non-immunization planning vaccines (category 2 vaccines) in China, and promote the sustainable development of the company's vaccine business. Tetanus is a highly serious potential lethal disease, and currently, vaccination is the most effective method of prevention.
Express News | AIM Vaccine Co Ltd - Application Been Submitted to Nmpa of China
Express News | AIM Vaccine - Pre-Applications for Clinical Trials for Mrna Rsv & Mrna Shingles/Herpes Zoster Vaccines of AIM Vaccine Submitted to US FDA
AIM Vaccine Co. Announces Upcoming Board Meeting
Analysis
Price Target
No Data
No Data